Bevacizumab(Hospices Civils de Lyon)

LONDON, July 14, 2022 (GLOBE NEWSWIRE) -- The “Colorectal Cancer – Global Drug Forecast and Market Analysis to 2028” market research report offered by GlobalData provides an overview of metastatic colorectal cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. Additionally, the report analyses topline metastatic colorectal cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period. The sales of CRC therapeutics totaled $7.6 billion in 2018 in the 8MM. The CRC market is anticipated to experience moderate growth at a CAGR of more than 3% by 2028. The global market growth is driven by the anticipated approval and launch of 9 pipeline therapies and label expansion of other agents. The US market will remain the largest market in this space, largely due to the rapid acceptance and reimbursement of premium-priced therapies. For more detailed statistics on CRC market sizing and forecast, download a sample report Colorectal Cancer Market Drivers A growing aging population, which will increase the number of incident cases of CRC High ACOT of new therapies, partially due to an increase in treatment duration, is attributed to improvements in drug efficacy that extend progression-free survival Decreasing patient share of cheap, generic chemotherapies, with shares shifting towards expensive branded agents The high price of biosimilars with relatively low rates of substitution Launch of first BRAF/MEK/EGFR triplet combination for BRAF V600-mutated mCRC patients For more insights on CRC market drivers and barriers, download a sample report Colorectal Cancer Market - Key Highlights Avastin to remain leader despite competition from novel mechanisms of action Unmet need will remain for the identification of new targets and biomarkers of response CRC pipeline moving towards precision medicine in both the early and metastatic setting The CRC market is expected to grow due to the incorporation of nine late-stage pipeline agents among the 8MM. For detailed insights on the CRC market, download a sample report Colorectal Cancer Market - Unmet Needs and Opportunities Assessment The greatest unmet need within mCRC is the lack of treatment options for RAS-mutated patients. Currently, the majority of patients, particularly RAS mutated patients, receive a limited repertoire of six cytotoxic chemotherapies and anti-angiogenesis agents. Patients can quickly become refractory to treatments, leaving physicians with no other treatment options. Therefore, understanding and overcoming mechanisms of resistance, specifically to anti-angiogenesis and anti-EGFR therapy, is a significant unmet need in CRC. Opportunity remains for novel targeted agents to gain a prime position in the mCRC market if they can be developed for RAS-mutated patients. For more insights on unmet needs and opportunities in the CRC market, download a sample report Colorectal Cancer Market - PipelineAssessment Companies typically target later-lines of treatment, which afford shorter duration times for trials and lower regulatory hurdles due to a higher unmet need. Several pipeline agents are positioned as third or fourth-line treatment options in mCRC. However, this setting is more competitive since the approval of Stivarga and Lonsurf, which are now the SOC for patients who progress after second-line treatment in the US and EU. For more insights on CRC drugs pipeline and forecast, download a sample report Colorectal Cancer Market -Competitive Landscape Roche is still regarded as the leading pharmaceutical company within the mCRC market based mostly on the strong performance of Avastin, the company’s major asset. Roche is expected to remain a strong player in the mCRC market due to physicians’ familiarity with Avastin and the slow erosion expected from bevacizumab biosimilars, as seen in other markets with biosimilar availability. Leading Companies in the Colorectal Cancer Market Roche Amgen Eli Lilly Bayer Bristol-Myers Squibb Merck KGaA Merck & Co Novartis Pfizer Sanofi Taiho To know more about leading companies in the CRC market, download a sample report Colorectal Cancer Market Report Scope Overview of metastatic colorectal cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. Topline metastatic colorectal cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period. Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting metastatic colorectal cancer therapeutics sales in the 8MM. Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. Analysis of the current and future market competition in the global metastatic colorectal cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to Buy Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines. Develop business strategies by understanding the trends shaping and driving the global metastatic colorectal cancer therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global metastatic colorectal cancer cancer market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Track drug sales in the global metastatic colorectal cancer therapeutics market from 2018-2028. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Related Reports Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update – Click here Metastatic Melanoma Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update – Click here Electronic Health Records (EHRs) – Analyzing Trends, Technologies, Physicians’ Adoption and Perceptions, Use Barriers and Opportunities, and Future Prospects – Click here Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here Colorectal Cancer Market Overview Market Size 2018 $7.6 billion CAGR (2018-2028) >3% Leading Companies Roche, Amgen, Eli Lilly, Bayer, Bristol-Myers Squibb, Merck KGaA, Merck & Co, Novartis, Pfizer, Sanofi, and Taiho FAQs What was the colorectal cancer market size in 2018? The CRC market size was valued at $7.6 billion in 2018. What is the colorectal cancer market growth rate? The CRC market is expected to grow at a CAGR of more than 3% during the forecast period. Which are the leading companies in the colorectal cancer market? The leading companies in the CRC market are Roche, Amgen, Eli Lilly, Bayer, Bristol-Myers Squibb, Merck KGaA, Merck & Co, Novartis, Pfizer, Sanofi, and Taiho. Table of Contents 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Colorectal Cancer: Executive Summary 2.1 CRC Market is Expected to Grow to $10.7B in 2028 2.2 Avastin to Remain Leader despiteCompetition from Novel Mechanisms of Action 2.3 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response 2.4 CRC Pipeline Moving Towards Precision Medicine in Both the Early and Metastatic Setting 2.5 What Do Physicians Think? 3 Introduction 3.1 Catalyst 3.2 Related Reports 3.3 Upcoming Related Reports 4 Disease Overview 4.1 Etiology and Pathophysiology 4.1.1 Etiology 4.1.2 Pathophysiology 4.2 Classification or Staging Systems for CRC 4.3 Clinical Presentation 5 Epidemiology 5.1 Disease Background 5.2 Risk Factors and Comorbidities 5.3 Global and Historical Trends 5.4 Forecast Methodology 5.4.1 Sources Used 5.4.2 Sources Not Used 5.4.3 Forecast Assumptions and Methods 5.5 Epidemiological Forecast for CRC 5.5.1 Diagnosed Incident Cases of CRC 5.5.2 Age-Specific Diagnosed Incident Cases of CRC 5.5.3 Sex-Specific Diagnosed Incident Cases of CRC 5.5.4 Diagnosed Incident Cases of CRC by Stage at Diagnosis 5.5.5 Diagnosed Incident Cases of CRC by Molecular Markers 5.5.6 Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis 5.5.7 Diagnosed Incident Cases of CRC by Sidedness 5.5.8 Five-Year Diagnosed Prevalent Cases of CRC 5.5.9 All-Time Diagnosed Prevalent Cases of CRC 5.6 Discussion 5.6.1 Epidemiological Forecast Insight 5.6.2 Limitations of the Analysis 5.6.3 Strengths of the Analysis 6 Disease Management 6.1 Screening and Diagnosis 6.1.1 Summary 6.1.2 Fecal Testing 6.1.3 Colonoscopy 6.1.4 Flexible Sigmoidoscopy 6.1.5 Computed Tomography Colonography 6.1.6 Recent and Emerging Advances 6.2 Treatment Guidelines 6.3 Clinical Practice 6.4 US 6.4.1 Screening 6.4.2 Treatment Pathways 6.4.3 Biomarker Testing 6.5 5EU 6.5.1 Screening 6.5.2 Treatment Pathways 6.5.3 Biomarker Testing 6.6 Japan 6.6.1 Screening 6.6.2 Treatment Pathways 6.6.3 Biomarker Testing 6.7 China (Urban) 6.7.1 Screening 6.7.2 Treatment Pathways 6.7.3 Biomarker Testing 7 Competitive Assessment 7.1 Overview 8 Unmet Needs and Opportunity Assessment 8.1 Overview 8.2 Improved Treatments for Patients with KRAS/NRAS Mutations 8.3 Continued Improvement in Precision Medicine 8.4 Reducing Age for Routine Screening 8.5 Overcoming Resistance to Angiogenesis and EGFR-Targeting Therapy 9 Pipeline Assessment 9.1 Overview 9.2 Promising Drugs in Clinical Development 10 Current and Future Players 10.1 Overview 10.2 Trends in Corporate Strategy 10.3 Roche 10.4 Amgen 10.5 Eli Lilly 10.6 Bayer 10.7 Bristol-Myers Squibb 10.8 Merck KGaA 10.9 Merck & Co. 10.10 Novartis 10.11 Pfizer 10.12 Sanofi 10.13 Taiho 11 Market Outlook 11.1 Global Markets 11.1.1 Forecast 11.1.2 Drivers and Barriers – Global Issues 11.2 US 11.2.1 Forecast 11.2.2 Key Events 11.2.3 Drivers and Barriers 11.3 5EU 11.3.1 Forecast 11.3.2 Key Events 11.3.3 Drivers and Barriers 11.4 Japan 11.4.1 Forecast 11.4.2 Key Events 11.4.3 Drivers and Barriers 11.5 China 11.5.1 Forecast 11.5.2 Key Events 11.5.3 Drivers and Barriers 12 Appendix 12.1 Bibliography 12.2 Abbreviations 12.3 Methodology 12.3.1 Forecasting Methodology 12.3.2 Diagnosed Patients 12.3.3 Drugs Included in Each Therapeutic Class 12.3.4 Launch and Patent Expiry Dates 12.3.5 General Pricing Assumptions 12.3.6 Individual Drug Assumptions for Marketed Products 12.3.7 Individual Drug Assumptions for Off-Label Products 12.3.8 Generic Erosion 12.3.9 Pricing of Pipeline Agents 12.4 Primary Research – Key Opinion Leaders Interviewed for This Report 12.5 Primary Research – Prescriber Survey 12.6 About the Authors 12.6.1 Analyst 12.6.2 Therapy Area Director 12.6.3 Epidemiologist 12.6.4 Epidemiology Reviewers 12.6.5 Global Director of Therapy Analysis and Epidemiology 12.6.6 Global Head and EVP of Healthcare Operations and Strategy 12.7 About GlobalData 12.8 Contact Us 12.9 Disclaimer About us GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies. Media Contacts GlobalData Mark Jephcott Head of PR EMEA mark.jephcott@globaldata.com cc: pr@globaldata.com +44 (0)207 936 6400

Clinical trial results suggest that a step strategy, in which patients with diabetic macular edema start with a less expensive medicine and switch to a more expensive medicine if vision does not improve sufficiently, gives results similar to starting off with the higher-priced drug. Clinical trial results from the DRCR Retina Network suggest that a specific step strategy, in which patients with diabetic macular edema start with a less expensive medicine and switch to a more expensive medicine if vision does not improve sufficiently, gives results similar to starting off with the higher-priced drug. The main complication of diabetic macular edema, fluid build-up in the retina that causes vision loss, is commonly treated with anti-vascular endothelial growth factor (VEGF) drugs. The trial was funded by the National Eye Institute (NEI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), both part of National Institutes of Health. Results of the trial, which examined a stepped regimen of anti-VEFG drugs Avastin (bevacizumab) and Eylea (aflibercept), were published today in the New England Journal of Medicine. "Our study showed that switching treatments when needed is a reasonable strategy," said Chirag Jhaveri, M.D., Austin Research Center for Retina, Texas, the lead study author. "Insurance companies often require clinicians to start with the less expensive treatment, so we really wanted to see how a specific treatment strategy using this approach would affect patient care." Diabetic macular edema is caused by diabetes-related alterations to retinal blood vessels. Symptoms include blurred vision. If untreated, vision loss can become permanent and progress to blindness. Retinal injections of anti-VEGF drugs can restore vision. The DRCR Retina Network previously showed that Avastin and Eylea improve visual acuity in people with diabetic macular edema. However, while Eylea is approved by the U.S. Food and Drug Administration to treat diabetic macular edema and results in better visual outcomes on average, off-label Avastin is much less expensive and is sometimes required by insurers as a first-line treatment. The study enrolled 270 participants with diabetic macular edema, some of whom received treatments in both eyes. At enrollment, all had best-corrected visual acuity between 20/50 and 20/320. Half the study eyes were assigned to Eylea from the start, and half were assigned to start with Avastin. For participants who needed treatment in both eyes, each eye started treatment with a different drug. Participants received either Avastin or Eylea injections every four weeks for 24 weeks. If eyes assigned Avastin failed to reach the pre-set improvement benchmarks starting at 12 weeks, the eye was switched to Eylea. After 24 weeks, physicians could taper down the frequency of injections as appropriate to maintain visual acuity. The study collected information about participants' retinal structure and visual acuity for two years. After two years, eyes in both groups had similar visual acuity outcomes, improving on average approximately three lines on an eye chart, compared to the trial's start. In the Avastin group, 70% of eyes switched to Eylea during the study. "While most participants on Avastin eventually switched to Eylea, they still had improvement during those initial weeks, even if they didn't hit our pre-set benchmarks," said Adam Glassman of the Jaeb Center for Health Research and director of the DRCR Retina Network coordinating center. "There are large cost disparities between these drugs, so differences in treatment strategies may have substantial cost implications." "We've demonstrated here one method to managing a step treatment, where the outcomes are similar to the best existing treatment protocol with Eylea," said Jennifer Sun, M.D., M.P.H., of Joslin Diabetes Center and Harvard Medical School, Boston, and chair of diabetes initiatives for the DRCR Retina Network. "Any time we can add to a clinician's toolbox, whether it's a new medication or a new approach to using existing medications, as in this study, it's a benefit for patients." The study was supported by NEI (EY014231) and NIDDK through the Special Diabetes Program for Type 1 Diabetes Research. Clinical trial number NCT03321513.